Evidence map›Paper›PMID 41924268›Full record

ArticleFrontiers in immunology2026

IQDMA disrupts STAT5 nuclear transport through CDC42-PAK2 axis collapse in cutaneous T-cell lymphoma.

Saptaswa Dey, Helena Sorger, Michaela Schlederer, Isabella Perchthaler, Martin Metzelder, Lukas Kenner, Richard Moriggl, Peter Wolf

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Saptaswa DeyDepartment of Dermatology and Venereology, Medical University of Graz, Graz, Austria.
Helena SorgerUnit of Functional Cancer Genomics, Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna, Austria.
Michaela SchledererDepartment of Pathology, Medical University of Vienna, Vienna, Austria.
Isabella PerchthalerDepartment of Dermatology and Venereology, Medical University of Graz, Graz, Austria.
Martin MetzelderDepartment of Pediatric and Adolescent Surgery, Medical University of Vienna, Vienna, Austria.
Lukas KennerDepartment of Pathology, Medical University of Vienna, Vienna, Austria.
Richard MorigglUnit of Functional Cancer Genomics, Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna, Austria.
Peter WolfDepartment of Dermatology and Venereology, Medical University of Graz, Graz, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: 'Cutaneous T-cell lymphoma (CTCL), particularly tumor stage mycosis fungoides (MF), presents significant therapeutic challenges due to limited treatment efficacy. This study addresses the unmet need for novel targeted therapies targeting the constitutively hyperactive STAT3/5 pathway. Methods: Kinome-wide profiling revealed that IQDMA selectively inhibits PAK2 (69%) and JAK3 (61%), kinases critical for STAT5 nuclear transport and activation. Using a C57BL/6 intradermal T-cell lymphoma model, we evaluated IQDMA efficacy against conventional psoralen + UV-A (PUVA) phototherapy. Results: IQDMA reduced tumor volume by 90.7% ( Conclusion: These findings establish a CDC42-PAK-STAT nuclear transport axis wherein IQDMA simultaneously inhibits PAK2 kinase activity and depletes its CDC42 scaffold, creating cytoplasmic pY-STAT5 retention that uncouples phosphorylation from transcriptional execution-a dual mechanism distinct from selective JAK inhibitors that warrants clinical evaluation.

Indexed as

cdc42 GTP-Binding ProteinLymphoma, T-Cell, Cutaneousp21-Activated KinasesSkin NeoplasmsSTAT5 Transcription FactorActive Transport, Cell NucleusAnimalsCell Line, TumorFemaleHumansMiceMice, Inbred C57BLSignal Transductioncdc42 GTP-Binding Proteinp21-Activated KinasesPAK2 protein, humanSTAT5 Transcription FactorCDC42cutaneous T-cell lymphomamulti-kinase inhibitormycosis fungoidesnuclear transporterPAK kinasequantitative proteomicsSTAT3 and STAT5

Identifiers

PMID41924268
PMCPMC13036142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.